Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients

BACKGROUND: BIBF 1120 is an oral, potent, tyrosine kinase inhibitor that simultaneously targets vascular endothelial growth factor receptors 1–3, platelet-derived growth factor receptors α and β, and fibroblast growth factor receptors 1–3, as well as FLT3 and Src. Currently, the molecule is in phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Bousquet, G, Alexandre, J, Le Tourneau, C, Goldwasser, F, Faivre, S, de Mont-Serrat, H, Kaiser, R, Misset, J L, Raymond, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242598/
https://www.ncbi.nlm.nih.gov/pubmed/22027711
http://dx.doi.org/10.1038/bjc.2011.440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242598/
https://www.ncbi.nlm.nih.gov/pubmed/22027711
http://dx.doi.org/10.1038/bjc.2011.440

Ejemplares similares